AbbVie
ABBV
#26
Rank
A$601.55 B
Marketcap
A$340.36
Share price
-1.15%
Change (1 day)
28.04%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

AbbVie (ABBV) - Total debt

Total debt on the balance sheet as of September 2025 : A$103.49 Billion

According to AbbVie's latest financial reports the company's total debt is A$103.49 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

AbbVie - Total debt on balance sheet (from 2011 to 2025)

Total debt by year

Year Total debt Change
2024-12-31A$107.94 B23.85%
2023-12-31A$87.16 B-6.25%
2022-12-31A$92.97 B-12.1%
2021-12-31A$105.77 B-5.49%
2020-12-31A$111.91 B17.43%
2019-12-31A$95.30 B66.56%
2018-12-31A$57.22 B19.55%
2017-12-31A$47.86 B-6.35%
2016-12-31A$51.11 B17.56%
2015-12-31A$43.47 B137.56%
2014-12-31A$18.30 B10.87%
2013-12-31A$16.50 B9.45%
2012-12-31A$15.08 B32114.79%
2011-12-31A$46.81 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
A$91.60 B-11.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$76.84 B-25.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$63.99 B-38.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
A$82.18 B-20.59%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
A$37.54 B-63.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
A$9.92 B-90.41%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
A$35.92 B-65.29%๐Ÿ‡ฌ๐Ÿ‡ง UK
AstraZeneca
AZN
A$49.12 B-52.53%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
A$0.64 B-99.38%๐Ÿ‡บ๐Ÿ‡ธ USA